CEREBRAL EMBOLIC PROTECTION DEVICES HOLD HUGE POTENTIAL TO LOWER THE PREVALENCE OF AORTIC STENOSIS. NORTH AMERICA TO WITNESS THE HIGHEST GROWTH
Cerebral Embolic Protection Devices Market is expected to exceed the market valuation of more than US$ XX million by 2027 expanding at a reasonable CAGR of around XX% during the forecast period (2021-2027). The reduction of strokes is an important factor to maintain the widespread use of Transcatheter aortic valve replacement (TAVR). Patients who have strokes after TAVR also have an elevated mortality risk. Every year more than 17,000 patients in Europe and 9,000 patients in North America suffer from TAVR. As pe a study it is witnessed that rate of strokes are 2.3% and TIA are 0.4% within 30 days. Additionally, amongst the people who had strokes 48.9% had them on the 1st day and 68.4% had them within 3 days of the treatment. The use of TAVR is increasing the need for managing strokes in the patients. In a 2019 study by Julia Seeger et al., cerebral embolic protection devices reduce the rate of strokes decreased from 3.6% without TAVR to 1.1% after using cerebral embolic protection device within 48 hours and from 4.6% to 1.4% respectively within 7 days.
For a detailed analysis of the Cerebral Embolic Protection Devices Market browse through – https://univdatos.com/report/cerebral-embolic-protection-devices-market
The primary therapeutic option for severe aortic stenosis is transcatheter aortic valve implantation (TAVI) that does not have high surgical risk. Up to 1.5 million people in the US suffer from aortic stenosis and around 500,000 of them have severe aortic stenosis. Cerebral embolic protection devices provide a mechanical barrier against the debris that is left after TAVI. Key factors that would increase the use of cerebral embolic protection devices are increase in prevalence of cardiovascular diseases, adoption of advanced surgical techniques, rise in geriatric population, and growth in healthcare investments. The high cost of device may hinder the growth of the market.
With the emergence of Coronavirus in 2020 and imposition of complete lockdowns, all surgical procedures and elective treatments were held at a standstill. The pandemic has caused profound health implications, apart from all the mortalities cause by Sars-CoV-2, it has also impacted the delivery of healthcare service that would otherwise have been a routine procedure. Aortic stenosis procedures are lifesaving and need inpatient procedures, however patients have delayed visiting the hospitals due to Covid-19. In the study conducted in Poland, the number of patients visiting the specialty center decreased from 50% to 34% before and after the pandemic and additionally, the procedure time and the hospital in-stay days were reduced from 7.5 hours to 4.2 hours and from 9 days to 7.5 days, respectively. Due to the reduction in surgeries the use of cerebral embolic protection devices was also lowered and thus effecting the market revenue as well.
For a detailed analysis of the Product in the Cerebral Embolic Protection Devices Market browse through – https://univdatos.com/report/cerebral-embolic-protection-devices-market
Based on product the cerebral embolic protection devices is fragmented into Sentinel System, Keystone Hearts Triguard Device and Embrella Embolic Deflector. The keystone hearts trigaurd device segment was valued at US$ XX million in 2020 and is likely to reach US$ XX million by 2027 growing at a CAGR of XX% from 2021-2027. The Triguar is the only CE mark approved system. Despite the increased fluoroscopic time, the deployment usually takes less than 10 min in 91% of cases. Sentinel can protect 74% of the brain volume, whereas embralla and triguard can protect 74% and 100% respectively. The cerebral protection market is estimated to grow with growing prevalence of valvular disfunction and more devices gaining FDA approval.
Based on end-user the market is segmented into hospital and others. The hospital segment generated revenue of US$ XX million in 2020 and is expected to grow at a CAGR of XX% during the forecast period to reach a market valuation of US$ XX million by 2027F. Cerebral embolic protection devices are used during the TAVR procedures which are performed in patients with aortic valve stenosis and cannot undergo open heart surgery. TAVR is a minimally invasive procedure and the cerebral embolic valve in placed procedure the beginning of the procedure and removed after its done. Patients generally need to stay in hospital for at least 6 days after the procedure to check any side effects. Even though using cerebral embolic protection devices can reduce the chances of strokes by collecting up to 90-95% of the debris. Hospitals are the most popular because of the extent of after procedure care one can get in hospitals.
Request for Sample of the report browse through – https://univdatos.com/request_form/form/422
Additionally, the report provides detailed initiatives that are being taken in the field of Cerebral Embolic Protection Devices, globally. The report provide a detailed analysis of regions including North America (the U.S, Canada, and Rest of North America), Europe (Germany, France, Spain, Italy, UK, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of Asia-Pacific), and the Rest of the World. North America dominated the market in 2020, with XX% share. Boston Scientific, Keystone Heart, and Endward Lifesceinces are some of the prominent players operating in the global Cerebral Embolic Protection Devices market. Several M&As along with partnerships have been undertaken by these players to make Cerebral Embolic Protection Devicess as cost-effective and as widely available as possible.
Cerebral Embolic Protection Devices Market Segmentation
Market Insight, by Product
- Clarets Sentinel System
- Keystone Hearts Triguard Device
- Embrella Embolic Deflector
Market Insight, by End-User
Market Insight, by Region
- North America Cerebral Embolic Protection Devices Market
- United States
- Rest of North America
- Europe Cerebral Embolic Protection Devices Market
- United Kingdom
- Rest of Europe
- Asia-Pacific Cerebral Embolic Protection Devices Market
- Rest of Asia-Pacific
- Rest of World Cerebral Embolic Protection Devices Market
Top Company Profiles
- Boston Scientific
- Keystone Heart
- Edwards Lifesciences